Agennix AG Schedules Conference Call on November 23rd to Discuss Third Quarter 2009 Financial Results

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - November 17, 2009) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that the Company will hold a conference call on Monday, November 23, 2009 at 3 PM CET/9 AM ET to discuss financial results for the third quarter of 2009 and provide a corporate update. The results will be published on November 23 in advance of the conference call.

Participants may listen via live webcast, accessible through the Agennix Web site at www.agennix.com or via telephone. A replay will be available on the Web site following the live event. The call will be conducted in English.

The dial-in numbers for the call are as follows:

Participants in Europe: 0049 69 667775756 0044 20 3003 2666 Participants in the U.S.: 1-646-843-4608 

Please dial in 10 minutes before the beginning of the call.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies. The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.